BrainsWay Ltd. reported positive pilot data on December 12, 2024, from an independent study evaluating an accelerated Deep TMS protocol for alcohol use disorder (AUD). The study, conducted at Stanford University, was published in the Brain Stimulation journal. It compared outcomes of patients treated with BrainsWay’s H7-Coil using an accelerated protocol against those treated by other means.
Patients receiving accelerated Deep TMS showed notable improvements in the follow-up period after treatment. This included lower percentages of heavy drinking days (3% versus 22%) and regular drinking days (15% versus 28%). The accelerated Deep TMS group also experienced lower relapse rates (60% versus 74%).
Following the pilot study's publication, the U.S. National Institutes of Health (NIH) awarded approximately $1.5 million to the research team to explore the efficacy of BrainsWay's Deep TMS system for substance use addictions. BrainsWay Deep TMS is not currently cleared by the FDA for the treatment of AUD.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.